Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H11NO3 |
| Molecular Weight | 145.1564 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)CCC(=O)CN
InChI
InChIKey=YUUAYBAIHCDHHD-UHFFFAOYSA-N
InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00992Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021415s004lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00992
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021415s004lbl.pdf
Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy. Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Methyl aminolevulinate is used for topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map00860 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | METVIXIA Approved UseMETVIXIA Cream in combination with Aktilite CL128 lamp red light illumination is indicated for treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratoses of the face and scalp in immunocompetent patients. This photodynamic therapy should be used in conjunction with appropriate lesion preparation in the physician’s office when other therapies are considered medically less appropriate. Launch Date1.09079999E12 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 g single, topical Dose: 1 g Route: topical Route: single Dose: 1 g Sources: |
unhealthy, adult n = 383 Health Status: unhealthy Condition: actinic keratosis Age Group: adult Population Size: 383 Sources: |
Disc. AE: Pain localised... AEs leading to discontinuation/dose reduction: Pain localised (1%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Pain localised | 1% Disc. AE |
1 g single, topical Dose: 1 g Route: topical Route: single Dose: 1 g Sources: |
unhealthy, adult n = 383 Health Status: unhealthy Condition: actinic keratosis Age Group: adult Population Size: 383 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Topical methyl aminolevulinate. | 2004 |
|
| Photodynamic therapy for subungual Bowen's disease. | 2004 Aug |
|
| [Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501): practical experiences in problem-patients with actinic keratoses and basal cell carcinomas]. | 2004 Dec |
|
| A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. | 2004 Jul |
|
| A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. | 2005 |
|
| Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. | 2005 Apr |
|
| Topical photodynamic therapy for Bowen's disease. | 2005 Feb |
|
| Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. | 2005 Feb |
|
| Pain, pain relief and other practical issues in photodynamic therapy. | 2005 Feb |
|
| Gateways to clinical trials. | 2005 Jul-Aug |
|
| Gateways to clinical trials. | 2005 Jun |
|
| [Reader's letter concerning K. Kreutzer, B.Bonnekoh, I. Franke, H. Gollnick. Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (Photdyn 501): practical experiences in problem patients with actinic keratoses and basal cell carcinomas. JDDG 2004,12:992-999]. | 2005 May |
|
| Gateways to clinical trials. | 2005 May |
|
| Influence of light exposure on the kinetics of protoporphyrin IX formation in normal skin of hairless mice after application of 5-aminolevulinic acid methyl ester. | 2005 Nov |
|
| Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas. | 2005 Sep-Oct |
|
| Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. | 2006 |
|
| Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. | 2006 |
|
| Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. | 2006 |
|
| Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. | 2006 Apr |
|
| Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. | 2006 Apr |
|
| Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice. | 2006 Apr |
|
| Successful treatment of necrobiosis lipoidica diabeticorum with photodynamic therapy. | 2006 Dec |
|
| Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. | 2006 Feb |
|
| The temperature dependence of porphyrin production in Propionibacterium acnes after incubation with 5-aminolevulinic acid (ALA) and its methyl ester (m-ALA). | 2006 Jan |
|
| Treatment of basal cell carcinoma with topical methylaminolaevulinate photodynamic therapy in an organ-transplant recipient. | 2006 Jan |
|
| Gateways to clinical trials. | 2006 Jan-Feb |
|
| Topical photodynamic therapy with methyl aminolevulinate to treat sebaceous hyperplasia in an organ transplant recipient. | 2006 Jun |
|
| A case of focal dermal hypoplasia (Goltz) syndrome with exophytic granulation tissue treated by curettage and photodynamic therapy. | 2006 Mar |
|
| Gateways to clinical trials. | 2006 May |
|
| The effect of skin permeation enhancers on the formation of porphyrins in mouse skin during topical application of the methyl ester of 5-aminolevulinic acid. | 2006 May 1 |
|
| Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. | 2006 Nov |
|
| Gateways to clinical trials. | 2006 Oct |
|
| A study comparing endogenous protoporphyrin IX induced by 5-ALA and ALA-methyl ester with exogenous PpIX and PpIX dimethyl ester in photodynamic diagnosis of human nasopharyngeal carcinoma xenografts. | 2006 Oct |
|
| Nonablative skin resurfacing: the role of PDT. | 2006 Sep |
|
| Photodynamic therapy: update 2006. Part 2: Clinical results. | 2007 Apr |
|
| Topical methyl aminolevulinate photodynamic therapy for the treatment of folliculitis. | 2007 Aug |
|
| Photodynamic treatment of cutaneous leishmaniasis. | 2007 Feb |
|
| Allergic contact dermatitis to methyl aminolevulinate (Metvix) cream used in photodynamic therapy. | 2007 Feb |
|
| Phototoxic reaction and porphyrin fluorescence in skin after topical application of methyl aminolaevulinate. | 2007 Feb |
|
| A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. | 2007 Jan |
|
| Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. | 2007 Jan |
|
| Chemopreventative thoughts for photodynamic therapy. | 2007 Jan |
|
| Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. | 2007 Jan |
|
| The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. | 2007 Jul |
|
| Photodetection of basal cell carcinoma using methyl 5-aminolaevulinate-induced protoporphyrin IX based on fluorescence image analysis. | 2007 Jul |
|
| Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. | 2007 Mar |
|
| Fluorescence diagnosis of face-located basal cell carcinomas: a new dermatological procedure which may help the surgeon. | 2007 Mar-Apr |
|
| Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. | 2007 May |
|
| Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. | 2007 May-Jun |
|
| Photodynamic therapy for cutaneous verrucous carcinoma. | 2007 Sep |
Patents
Sample Use Guides
Using a spatula, apply a layer of METVIXIA Cream (Methyl aminolevulinate) about 1 mm thick to the lesion and the surrounding 5 mm of normal skin. Do not apply more than one gram (half tube) of METVIXIA Cream per treatment session.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
||
|
WHO-ATC |
L01XD03
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
||
|
NCI_THESAURUS |
C1420
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
||
|
WHO-VATC |
QL01XD03
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
||
|
NDF-RT |
N0000175846
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
724125
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
585NM85KYM
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
SUB22645
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
585NM85KYM
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
DB00992
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
337068
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | RxNorm | ||
|
C475457
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
DTXSID3048570
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
157922
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
168
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
M7360
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | Merck Index | ||
|
METHYL AMINOLEVULINATE
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
100000087993
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
C76305
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY | |||
|
33320-16-0
Created by
admin on Wed Jul 05 23:03:46 UTC 2023 , Edited by admin on Wed Jul 05 23:03:46 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
